Table 1 Clinical details of JIA patients and healthy donors
Clinical parameters | Healthy donors n = 25 | JIA patients n = 25 | p value |
|---|---|---|---|
Female/Male (n/n) | 13/12 | 14/11 | |
Age (years) | 27.21 ± 2.54 | 25.11 ± 7.21 | |
Disease duration (years) | – | 13.47 ± 5.47 | |
Remission duration (years) | – | 3.52 ± 3.33 | |
RF + (n) | 0 | 1 | |
ACPAs + (n) | 0 | 1 | |
CRP (mg/dl) | 0.95 ± 1.19 | 2.88 ± 5.54 | |
ESR (mm/h) | 6.53 ± 3.82 | 5.47 ± 3.54 | |
C3 (mg/dL) | 124.15 ± 12.51 | 124.16 ± 16.03 | |
C4 (mg/dL) | 20.84 ± 4.01 | 25.97 ± 7.19 | 0.017 |
JIA subtypes | |||
Systemic (%) | – | 4 | |
Oligoarthritis (%) | – | 24 | |
RF-negative polyarthritis (%) | – | 20 | |
RF-positive polyarthritis (%) | – | 4 | |
Psoriatic (%) | – | 24 | |
Enthesitis-related arthritis (%) | – | 24 | |
Undifferentiated (%) | – | 0 | |
Metabolic profile | |||
BMI | 22.49 ± 3.13 | 22.70 ± 4.32 | |
Glucose (mg/dl) | 83.64 ± 6.38 | 76.47 ± 11.20 | |
Insulin (mU/L) | 7.10 ± 3.52 | 5.79 ± 2.76 | |
HbA1c (%) | 5.12 ± 0.11 | 5.15 ± 0.30 | |
Total Cholesterol (mg/dl) | 163.57 ± 24.75 | 180.26 ± 29.92 | 0.046 |
HDL-Cholesterol (mg/dl) | 52.21 ± 10.23 | 57.63 ± 15.22 | |
LDL-Cholesterol (mg/dl) | 95.50 ± 21.46 | 105.00 ± 29.17 | |
Triglycerides (mg/dl) | 75.35 ± 33.87 | 83.31 ± 50.58 | |
ApoA (mg/dl) | 136.35 ± 25.50 | 140.77 ± 24.16 | |
ApoB (mg/dl) | 69.64 ± 15.63 | 77.11 ± 18.36 | |
Treatments | |||
No treatment (n) | – | 10 | |
Corticosteroids (n) | – | 4 | |
Salazopyrin (n) | – | 2 | |
NSAIDS (n) | – | 3 | |
Methotrexate (n) | – | 2 | |
Anti-TNF-α (n) | – | 4 | |